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Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly, Caucasian
populations. There is strong evidence that mitochondrial dysfunction and oxidative stress play a role in the cell
death found in AMD retinas. The purpose of this study was to examine the association of the Caucasian
mitochondrial JTU haplogroup cluster with AMD. We also assessed for gender bias and additive risk with known
high risk nuclear gene SNPs, ARMS2/LOC387715 (G > T; Ala69Ser, rs10490924) and CFH (T > C; Try402His,
rs1061170).
Methods: Total DNA was isolated from 162 AMD subjects and 164 age-matched control subjects located in Los
Angeles, California, USA. Polymerase chain reaction (PCR) and restriction enzyme digestion were used to identify
the J, U, T, and H mitochondrial haplogroups and the ARMS2-rs10490924 and CFH-rs1061170 SNPs. PCR amplified
products were sequenced to verify the nucleotide substitutions for the haplogroups and ARMS2 gene.
Results: The JTU haplogroup cluster occurred in 34% (55/162) of AMD subjects versus 15% (24/164) of normal
(OR = 2.99; p = 0.0001). This association was slightly greater in males (OR = 3.98, p = 0.005) than the female population
(OR = 3.02, p = 0.001). Assuming a dominant effect, the risk alleles for the ARMS2 (rs10490924; p = 0.00001) and CFH
(rs1061170; p = 0.027) SNPs were significantly associated with total AMD populations. We found there was no
additive risk for the ARMS2 (rs10490924) or CFH (rs1061170) SNPs on the JTU haplogroup background.
Conclusions: There is a strong association of the JTU haplogroup cluster with AMD. In our Southern California
population, the ARMS2 (rs10490924) and CFH (rs1061170) genes were significantly but independently associated
with AMD. SNPs defining the JTU mitochondrial haplogroup cluster may change the retinal bioenergetics and play
a significant role in the pathogenesis of AMD.
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Age-related macular degeneration (AMD) is the leading
cause of blindness among the elderly population in the
developed world and it is anticipated that its prevalence
will rise. Risk factors for AMD include Caucasian race,
smoking and family history. Clinical characteristics of
early AMD are subretinal drusen and loss of retinal* Correspondence: mkenney@uci.edu
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reproduction in any medium, provided the orpigment epithelium (RPE). Late AMD exists in two
forms: dry AMD (atrophic, stage 4) which has progres-
sive loss of RPE cells and overlying photoreceptors and
wet AMD (neovascular, stage 5) which makes up ap-
proximately 15% of the cases and is characterized by
choroidal neovascularization and disciform scar forma-
tion. Both forms can result in severe central vision loss.
Mitochondria are critical organelles that provide en-
ergy to the cell via oxidative phosphorylation (OXPHOS).
Mitochondria are unique in that they have their own
DNA (mtDNA) which is highly polymorphic with 16,569Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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OXPHOS protein subunits, 2 ribosomal RNAs and 22
transfer RNAs [1,2]. The mtDNA lacks histones and has
poor DNA repair systems so it is at greater risk of da-
mage compared to nuclear DNA. Human retinal cells are
very metabolically active and have evidence of oxidative
damage in the retinal mtDNA, including high degrees of
pathologic heteroplasmy, large deletions and nucleotide
substitutions. Recently, studies have shown that aging
and AMD retinas have increased mitochondrial struc-
tural abnormalities and elevated levels of mtDNA da-
mage [3-7].
Another mechanism by which diseases can occur is
through the association of mtDNA haplogroups which
represent different ethnic populations of the world. A spe-
cific haplogroup is defined by variations in mtDNA
sequences within the maternal lineages that have accumu-
lated over thousands of years and represent the geographic
origin of that population. The oldest haplogroups (L1-L3)
originated from Africa (130 K-170 K years) while the most
recent haplogroups (A, B, C, D, X) originated within the
North and South American continents (18 K-34 K years)
(www.mitomap.org). The European haplogroups (H, I, J,
K, T, U, V, W and X) are approximately 30 K-50 K years
old. It is likely that the haplogroup single nucleotide poly-
morphism (SNP) variants may have functional conse-
quences. Since mitochondria are critical for energy
production, the haplogroup-related SNPs may be related
to partial uncoupling of OXPHOS and decreased effi-
ciency of ATP production [8-10]. This means that each
haplogroup, with its different set of SNPs, can have unique
bioenergetic properties and responses to oxidative stres-
sors. The haplogroup defining SNPs may modify the
required mitochondrial energetics of that population to
meet the needs of their environment [11] and therefore
may have varying biological effects on the cells.
Studies have shown that the age-related diseases, such
as Alzheimer’s and Parkinson’s, are associated with
specific haplogroups [12-15]. Large soft drusen, retinal
pigment abnormalities and the wet forms of AMD, an
age-related eye disease, have also been shown to be asso-
ciated with some European haplogroups [16-20]. Corre-
lations between other ocular diseases and haplogroups
are also being reported. Susceptibility to pseudoexfolia-
tion glaucoma is decreased in patients with a U hap-
logroup but increased with T or L2 haplogroups [21,22].
In a Saudi Arabian population, there is an increased risk
of primary open-angle glaucoma in patients with the
African L haplogroups, excluding L2 haplogroup [23]. In
addition, there is a higher prevalence of diabetic retino-
pathy in type 2 diabetic patients with the mtDNA T hap-
logroup background [24].
There are two major susceptibility genes associated
with AMD in certain populations. The CFH genepolymorphism (rs1061170), T1277C (Tyr402His) has
been associated with the development and progression
of AMD [25-29] in Caucasian populations but not
Asians [30-32]. The CFH protein blocks C3 to C3b acti-
vation, causes C3b degradation, and thereby regulates
the alternative complement pathway. Both aging and
smoking can decrease the CFH plasma levels [33] and
which can lead to increased inflammation [34,35]. The
ARMS2/LOC387715 gene polymorphism (rs10490924)
is a missense SNP transversion from G > T (Ala69Ser).
In a North American population, TT homozygosity is
associated with the wet and dry forms of advanced
AMD, showing an allele-dose effect [36]. Studies based
on Japanese AMD populations have found that the SNP
(rs10490924) in the LOC387715 gene is associated with
the wet form of AMD, [37-39] which has been con-
firmed in both American [40-42] and Indian populations
[43]. Fritsche and coworkers expressed the LOC387715
mRNA [44] and reported a mitochondrial association
[45] although this has not been found by others [46].
Some investigators suggest that the ARMS2 gene codes
for a secreted protein that binds to extracellular matrix
[47]. Baas and coworkers have shown significant associ-
ation for three SNPs of the glucose transporter gene
(SLC2A1) in a single cohort, but when applied to
additional study populations, the results showed an in-
consistent, non-significant association [48]. Based upon
these findings, they suggest that across populations there
is heterogeneity of AMD risk factors which exists as the
rule rather than the exception.
It has already been shown that the clinical phenotypes
of diseases can be influenced through synergistic effects of
nuclear genes with the mitochondrial genome [49,50]. For
example, Leber’s hereditary optic neuropathy (LHON)
individuals harboring the milder mutations at positions
11778, 14484, and 10663 have increased severity and
probability of blindness if they have a J haplogroup back-
ground [49,51]. The LHON patients with the 3460 muta-
tion on a Uk mtDNA haplogroup background were higher
risk for vision loss [52] while the H haplogroup protected
from the disease [53]. In contrast, the J haplogroup back-
ground in HIV infected patients protects them against
progression of neuroretinal disorder (NRD) [54]. The
present study was designed to assess the frequency of the
JTU haplogroup cluster in our AMD population and
examine the potential additive associations of the ARMS2-
rs10490924 and CFH-rs1061170 risk alleles.
Methods
AMD classification
The subjects underwent a complete dilated ophthalmic
examination by Board certified ophthalmologists (D.S.B.,
A.B.N., K.S., M.C.K.) including both slit lamp examin-
ation and an indirect ophthalmic exam with a 90 diopter
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cence and/or indocyanine green angiography were per-
formed. The photos and angiograms were read by
masked graders who were board certified retinal specia-
lists [29]. Subjects were graded according to the Clinical
Age-Related Maculopathy Staging System (CARMS)
[55]. Grade 3 had large soft drusen or several intermedi-
ate size drusen or drusenoid retinal pigment epithelial
detachments and for this study is referred to as Early
AMD. In this study the term Late AMD is the combi-
nation of Grade 4 which is geographic atrophy and grade
5 which is neovascular or serous exudative AMD. No
stage 1 or 2 AMD patients were included in this study.
Data collection
Institutional review board approval was obtained from
the University of California in Irvine (#2003-3131) and
from Cedars-Sinai Medical Center (#1708) with prior pa-
tient consent. This study examined DNA samples
obtained from 162 AMD patients and 164 age-matched
controls (Table 1). The patients with AMD were mainly
from a private practice retina specialist office (Retina-
Vitreous Associates Medical Group) and the controls
were from a private general ophthalmology office
(American Eye Institute). The offices are approximately
2 miles apart and serve the same demographic and eth-
nic populations, which is predominantly European hap-
logroup Caucasian. There was no statistical difference in
the ages between the case and control populations
(78.03 ± 0.68 versus 76.4 ± 0.56, p = 0.06). When analyzed
according to gender, the mean ages were not signifi-
cantly different (female-AMD, 78.29 ± 0.85 versus fe-
male-control, 76.61 ± 0.72, p = 0.14; and male-AMD,
77.32 ± 1.17 versus male-control, 76.1 ± 0.90, p = 0.40).
In the AMD population there were twice as many
females as males (109 versus 53) but the mean ages were
similar (female-AMD 78.29 ± 0.85 and male-AMD,
77.32 ± 1.17, p = 0.72). The control population had 94
females to 70 males with similar ages (female-control
76.61 ± 0.72 and male-control, 76.10 ± 0.90, p = 0.65).Table 1 Demographics of AMD and normal subjects
Total AMD Normal p-value
n 162 164
Median Age 79 75
Mean Age ± SEM 78.03 ±0.68 76.4 ±0.56 0.06
Female (n) 109 94
Median Age 79 75
Mean Age ± SEM 78.29 ±0.85 76.61 ±0.72 0.14
Male (n) 53 70
Median Age 78 75
Mean Age ± SEM 77.32 ±1.17 76.1 ±0.90 0.40
SEM, standard error of the mean; n, number of samples.10 ml sample of peripheral blood was collected in tubes
containing 10 mM EDTA. DNA extraction was per-
formed with a DNA extraction kit (PUREGENE, Minne-
apolis, MN).
Mitochondrial haplogroup analyses
Samples were analyzed using PCR, restriction enzyme
digestion and sequencing of the mtDNA to identify the
mitochondrial haplogroup of each patient as described
previously [18]. The SNPs defining the J haplogroup
were G13708A, C16069T and T16126C (Figure 1). The
T defining SNPs were A4917G and G13368A. The U de-
fining SNPs were positive for A12308G but negative for
G9055A. The H defining SNPs were T7028C and G73A.
DNA amplification
Polymerase Chain Reaction (PCR) was used to amplify
desired DNA regions from 100 ng of DNA. The PCR
reaction for the region flanking the G > T SNP of
rs10490924 in the ARMS2 was performed with an an-
nealing temperature of 60°C (forward primer sequence
50GCACCTTTGTCACCACATT30 and reverse primer
sequence 50GCCTGATCATCTGCATTTCT30). The pri-
mers and PCR conditions for the CFH-rs1061170 gene
were described previously [29].
Restriction digestion
Restriction endonuclease digestion was performed
following PCR amplification. Restriction enzymes were
used to digest PCR products, according to theFigure 1 Schematic of circular mtDNA showing SNPs that
define the H, J, T and U haplogroups. Cyt B, Cytochrome B; ND,
NADH dehydrogenase; CO, Cytochrome c oxidase; ATPase, ATP














Figure 2 Sequencing and restriction enzyme digestion of the ARMS2-rs10490924 SNP. Panel: Left – Sequence chromatogram of the GG
homozygote, GT heterozygote and TT homozygote of the ARMS2-rs10490924 SNP. Right - 1.5% agarose gel showing the single lower band
representing GG and the single higher band being TT. The double band represents heterozygous GT after PCR and digestion with PvuII. M =marker.
Table 2 mtDNA cluster haplogroups and gender
AMD Normal OR 95%CI p-value
TOTAL
H 51/162 (31%) 50/164 (30%) 1.05 0.66-1.67 0.94
JTU cluster 55/162 (34%) 24/164 (15%) 2.99 1.74-5.15 0.0001
FEMALE
H 35/109 (32%) 30/94 (32%) 1.00 0.56-1.82 0.90
JTU cluster 37/109 (34%) 16/94 (17%) 3.02 1.56-5.85 0.001
MALE
H 16/53 (30%) 20/70 (29%) 1.08 0.49-2.37 0.99
JTU cluster 18/53 (34%) 8/70 (11%) 3.98 1.57-10.10 0.005
OR, Odds Ratio; CI, Confidence Interval.
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Biolabs, Ipswich, MA). Digested samples were separated
by electrophoresis on 1.5% agarose gels and stained with
ethidium bromide. Genotyping according to DNA frag-
ment size following digestion and electrophoresis is as
follows:
For ARMS2-rs10490924 SNP (product size 257 bp),
PvuII will digest the wild type G allele into fragments of
129 and 128 bp, while an allele with the G > T SNP does
not cut and appears as a band at 257 bp (Figure 2). Ac-
cordingly, bands appear at 257, 129, and 128 bp in a GT
heterozygote.
The PCR product for CFH-rs1061170 SNP was digested
with NlaIII restriction enzyme as described previously
[29]. The uncut product is 469 bp and the length of the
restriction fragments for the T allele are 6, 74, 89 and
300 bp while the C allele appears as 6, 74, 85, 89, and
215 bp (data not shown).
Sequencing
Once genotypes were assigned by means of restriction
digest, samples of PCR product were taken from each of
the alleles for the ARMS2-rs10490924 SNP in order to
confirm the validity of the genotypes as determined by
the digests. These samples were treated with ExoSAP-IT
(USB Corp. Cleveland, OH) according to the manufac-
turer’s protocol. The samples were then sequenced at
the UCLA Sequencing and Genotyping Core, Los
Angeles, CA. All sequenced samples matched the geno-
types obtained by restriction digest.
Statistical analysis
Statistical analysis was performed using Simple Interactive
Statistical Analysis (SISA) internet software (QuantitativeSkills, The Netherlands) and the Fisher’s exact test using
GraphPad Prism software (San Diego, CA).
Results
A cohort of 162 case and 164 control subjects were ge-
notyped for individual Caucasian mitochondrial hap-
logroups J, T, U and H. Genotypes were determined
according to the specified migration pattern of the
digested products and the data were used to assign the
representative haplogroups (Table 2). Statistical analyses
were carried out for the occurrence of each haplogroup
within the case and control populations. The occurrence
of the common Caucasian H haplogroup was similar in
the case (31%, 51/162) and control populations (30%,
50/164, p = 0.94, Table 2). In contrast, the northern
European/Caucasian haplogroup JTU cluster was 34%
(55/162) of the total AMD population but only 15% (24/
164) of the age-matched normal population (OR = 2.99;
95% CI = 1.74-5.15; p = 0.0001). These findings show that
AMD is more commonly found in subjects with the JTU
Table 3 Frequency of alleles in AMD and normal
populations
Early Late Total AMD Normal
ARMS2 Allele T (risk) 50/120 96/202 146/322 91/328
(42%) (48%) (45%) (28%)
ARMS2 Allele G 70/120 106/202 176/322 237/328
(58%) (52%) (55%) (72%)
CFH Allele C (risk) 43/110 83/188 126/298 94/326
(39%) (44%) (42%) (29%)
CFH Allele T 67/110 105/188 172/298 232/326
(61%) (56%) (58%) (71%)
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the H haplogroup. We then segregated the samples
based on their gender and analyzed the distribution. The
JTU cluster was slightly higher for AMD in males com-
pared to controls (OR = 3.98, p = 0.005) than females
versus controls (OR = 3.02, p = 0.001) but this may be
related to the smaller numbers of males in the case
population.
In the total (early + late) AMD population, the ARMS2-
rs10490924 SNP, was represented in a frequency of allele
distribution of 45% high risk T allele while the normal
population was 28% T allele (p < 0.00001, Table 3). The
early AMD subset had 42% T allele frequency (p = 0.007)
and the late AMD subset had 48% T distribution (p <
0.00001) compared to the 28% T allele in the control
group. The allele distribution for the CFH SNP was 42%
high risk C allele in the total AMD group compared to
29% in the normal populations (p = 0.0006), while the late
AMD population had 44% C allele distribution (p =
0.0.0006). In the early AMD populations the C risk allele
distribution was 39% (p = 0.06).
The dominant odds ratios (OR) were calculated by
determining the prevalence of the risk allele (heterozy-
gous + homozygous risk alleles) compared to normal
subjects with no copy of the risk allele (homozygous
wildtype; Table 4). Assuming a dominant effect, the T
risk allele for the ARMS2-rs10490924 SNP wasTable 4 Genotypes and odds ratios in age-related macular de
assuming a dominant effect
Early AMD L
ARMS2 Homozygous T (risk) 11/60 (18%) 1
ARMS2 Homozygous G 21/60 (35%) 2
ARMS2 Heterozygous 28/60 (47%) 5
OR (p-value) 1.81 (0.07) 3
CFH Homozygous C (risk) 11/55 (20%) 1
CFH Homozygous T 23/55 (42%) 2
CFH Heterozygous 21/55 (38%) 4
OR (p-value) 1.27 (0.54) 2
OR, Odds Ratio.significantly associated with AMD (OR = 4.72; p =
0.00001). This high risk allele was also associated in the
late AMD (OR = 3.13, p = 0.0001) but not the early
AMD group (OR = 1.81; p = 0.07). With respect to C risk
allele of the CFH-rs1061170 SNP, assuming a dominant
risk, the OR was 1.71 for the total AMD population
compared with the control population (p = 0.027). The
increased association for the C allele was also found in
this late AMD population (OR = 2.05; p = 0.014). This
demonstrates that our case population had ARMS2-
rs10490924 and CFH-rs1061170 high risk alleles asso-
ciated with AMD which is similar to results found in the
literature [56].
We then examined the association of the high risk
nuclear alleles for subjects that had mitochondrial back-
grounds of either H haplogroup or the JTU haplogroup
for the case and control populations (Table 5). For the
ARMS2 gene, we found 18% of the AMD subjects had
the homozygous T with the H haplogroup (9/50) while
18% had the JTU cluster haplogroup (10/55). The homo-
zygous high risk C allele of the CFH gene was associated
with 23% of the H haplogroup (11/47) and 18% of the
JTU cluster haplogroup (9/51). Then we analyzed the
likelihood of increased risk for the ARMS2-rs10490924
or CFH-rs1061170 SNPs on the JTU cluster background
versus the H background in AMD subjects (Table 6).
There were weak odds ratios and no significant differ-
ences when we compared the H and JTU cluster back-
grounds, indicating that having a JTU background may
not have additive risk for the ARMS2-rs10490924 or
CFH-rs1061170 SNPs when compared to the H hap-
logroup background. However, additional studies using
larger populations are needed to investigate the interac-
tions between risk factors and “mtDNA defined” genetic
backgrounds since the power of our study is low.
Discussion
Increasing evidence shows that mitochondrial dysfunc-
tion plays a role in development and progression of
AMD. Haplogroups are defined by an accumulation ofgeneration (AMD) and normal patients with risk allele,
ate AMD Total AMD Normal
9/101 (19%) 30/161 (19%) 10/164 (6%)
4/101 (24%) 45/161 (28%) 83/164 (51%)
8/101 (57%) 86/161 (53%) 71/164 (43%)
.13 (0.0001) 4.72 (0.00001)
8/94 (19%) 29/97 (20%) 16/163 (9.8%)
9/94 (31%) 52/97 (35%) 85/163 (52%)
7/94 (50%) 68/97 (45%) 62/163 (38%)
.05 (0.014) 1.71 (0.027)
Table 5 Genotypes found in AMD subjects and normal
subjects with either the H haplogroup background or
JTU haplogroup background
Haplogroup and ARMS2 (G > T)
Homozygous T Homozygous G Heterozygous
AMD
H 9/50 (18%) 11/50 (22%) 30/50 (60%)
JTU cluster 10/55 (18%) 17/55 (31%) 28/55 (51%)
Normal
H 5/52 (10%) 23/52 (44%) 24/52 (46%)
JTU cluster 0/24 (0%) 11/24 (46%) 13/24 (54%)
Haplogroup and CFH (T > C)
Homozygous C Homozygous T Heterozygous
AMD
H 11/47 (23%) 14/47 (30%) 22/47 (47%)
JTU cluster 9/51 (18%) 18/51 (35%) 24/51 (47%)
Normal
H 6/51 (12%) 24/51 (47%) 21/51 (41%)
JTU cluster 1/24 (4%) 12/24 (50%) 11/24 (46%)
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sentative of that specific geographic population. The
most common Caucasian European haplogroups is H
and it is the basis for the Cambridge reference sequence
by MitoMap (www.MitoMap.org). The J, T, and U hap-
logroups have their own defining SNPs, some of which
are non-synonymous (amino acid changing) and others
which occur in the non-coding MT-Dloop, a region cri-
tical for replication and transcription. Different SNP
variants may change retinal bioenergetics and energy
production levels causing a) decreased OXPHOS effi-
ciencies; b) increased ROS production; c) elevated oxida-
tive stress and apoptosis and d) elevated levels of cell
death, which may contribute to AMD and other retinal
diseases. It is well recognized that oxidative stress is
associated closely with aging and age-related diseases.
Therefore, it must be noted that while investigating the
mtDNA variants that define the haplogroups, it is im-
portant to assess the ages of the case and control popu-
lations because minor age differences may lead to false
positive associations.Table 6 Odds ratio of risk alleles in AMD population on a JTU
Homozygous Risk Allele OR;
(p-value); 95%CI
ARMS2
JTU Cluster vs H 0.51; (0.28) 0.185 – 1.387
CFH
JTU Cluster vs H 0.326; (0.529) 0.037 – 2.87
OR, Odds Ratio; CI, Confidence Interval.The present study showed the mitochondrial hap-
logroup cluster JTU was significantly associated with the
development of AMD (p = 0.0001) while H, the most
common Caucasian haplogroup, had no risk association
with the disease. Our results support previous findings
that the haplogroup T-associated SNP A4917G is an in-
dependent predictor of AMD [17] and two variants of
the T2 haplogroup, A11812G of MT-ND4 and A14233G
of MT-ND6, are 2.5 times more likely to be associated
with advanced AMD than the age-matched control sub-
jects [19]. Analyses of Middle European Caucasians
showed that the haplogroup J was associated with wet
AMD while the H haplogroup was protective [20]. In an
Australian population, the early AMD signs of large soft
drusen and retinal pigment abnormalities have been
associated with J and U haplogroups [16]. The OXPHOS
“uncoupling” of mtDNA associated with the J, T and U
haplogroups are more commonly found in populations
that originated in Northern European colder climates
and these are the ones that are often associated with
altered risk in the aging-related disorders of Parkinson’s
disease and Alzheimer’s disease, and now AMD. Recent
studies have shown that haplogroup J cybrids (cytoplas-
mic hybrids) and Uk cybrids differ in the mtDNA con-
tent, levels of ATP production and OXPHOS capacity
compared to H haplogroup cybrids [57,58]. This has led
to speculation that mtDNA variants that define hap-
logroups might mediate cellular signaling pathways and
influence the susceptibility to different diseases.
Upon recalculation of the risks based on gender, we
also found a slightly higher Odds Ratio associated with
males as compared to females but further analyses with
larger numbers of subjects are needed to definitively
make this association. It is possible that nuclear modifier
elements may influence gender bias associated with
aging and/or diseases. One study showed that cells with
the J haplogroup backgrounds can increase mtDNA copy
numbers more rapidly than the H haplogroups [59]. It
has been proposed that the SNPs that define the JTU
clusters may partially “uncouple” OXPHOS and alter the
mitochondrial energy production efficiency [8]. Sperm
with the T and U haplogroups showed lower motility
than the sperm with the common European haplogrouphaplogroup background versus H background




1.845; (0.25) 0.766-4.439 1.01; (0.86) 0.457 – 2.235
1.125; (0.99) 0.426 – 2.97 1.21; (0.89) 0.455 – 3.213
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more calories would be consumed for the same amount
of ATP produced and as a result, the mitochondrial ROS
levels would be higher [9,10]. These elevated ROS levels
could in turn lead to higher levels of oxidative damage
to DNA, lipids and proteins. As the retina is one of the
most metabolically active tissues in the body, even a par-
tial decline in the energy production efficiency might
significantly affect the retinal function.
Rivera et al. implicated the G > T (Ala69Ser) SNP in
exon 1 of LOC387715 (ARMS2-rs10490924) as a pos-
sible susceptibility candidate for AMD, accounting for
linkage to the 10q26 region [61]. Shortly thereafter,
Schmidt et al., conducted a study that also identified the
G > T polymorphism in ARMS2-rs10490924 as an
AMD-susceptibility allele [62]. Further studies revealed a
strong association between AMD populations and the
number of G > T alleles at ARMS2-rs10490924 [63,64].
Assuming a dominant effect, we found that the ARMS2-
rs10490924 risk allele is associated with the late form of
AMD but not the early form. Our findings agree with
Ross and coworkers who also showed LOC387715 asso-
ciated with the more advanced clinical-based cases but
not the early AMD cases [65]. It is also consistent with
two other studies that show that the presence of the T
risk allele for the LOC387715 gene is associated with the
more severe, wet form of AMD [39,41]. From our case–
control study, we found that the association between the
T allele for the ARMS2 gene (rs10490924) and AMD is
independent of the patient’s mtDNA haplogroup back-
ground. However, our population numbers are relatively
small and our results need to be corroborated with a lar-
ger size population.
Our results show strong evidence for the CFH risk al-
lele C (rs1061170) to be a susceptibility allele for AMD
in our population. As the allele T is more common in
the control population, it indicates that tyrosine at resi-
due 402 may have a protective function. In addition to
the compelling CFH genetic studies, there is additional
biological evidence, such as localization of complement
protein in drusen deposits in AMD patients that impli-
cate inflammation in the pathogenesis of AMD. The as-
sociation of AMD with nuclear high-risk genes varies
among the European, Japanese, Chinese and other ethnic
populations [30,66-68]. As ethnic variations can be iden-
tified through the evolutionary SNPs that categorize a
variety of ancestral mitochondrial haplogroups and mi-
gration patterns, [9,10,69,70] we hypothesized that SNP
variations of mtDNA may interact differently with the
high risk nuclear genes in AMD. We analyzed both the
high risk nuclear genes and the Northern European JTU
haplogroup cluster with respect to AMD. Our data
shows that the mitochondrial JTU haplogroup cluster
was an independent risk factor for AMD and notadditive to the risk alleles of ARMS2-rs10490924 and/or
CFH-rs1061170 SNPs. However, future studies with lar-
ger populations will need to be conducted to determine
if the individual J, T or U haplogroups have additive risk
to the nuclear risk genes or environmental factors such
as smoking and obesity [62,64].
Conclusions
Age-related macular degeneration (AMD) is the major
cause of vision loss in the elderly, Caucasian population.
In this study, analyses of 326 individuals showed that the
JTU haplogroup cluster occurred in 34% of AMD
subjects versus 15% of normal subjects (OR = 2.99;
p = 0.001). This association was slightly greater in males
(OR = 3.98, p = 0.005) than the female populations
(OR = 3.02, p = 0.001). Assuming a dominant effect, the
risk alleles of two known nuclear genes, ARMS2 (G > T;
Ala69Ser, rs10490924) and CFH (T > C; Try402His,
rs1061170), were significantly associated with the AMD
populations (p = 0.0001 and p = 0.0.027). However, we
found there was no additive risk for the ARMS2 or CFH
SNPs on the JTU haplogroup backgrounds. Our findings
are significant because this data suggests that (1) both
nuclear and mitochondrial genomes are significantly
but independently associated with AMD, and (2) the
Northern European ancestral mtDNA sequence variants
may have SNPs that contribute to altered mitochondrial
efficiency associated with AMD.Abbreviations
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